Related Experiment Video

Updated: Jun 30, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

ASA404: update on drug development

Farah Rehman1, Gordon Rustin

  • 1Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex, HA6 2RN, UK.

Expert Opinion on Investigational Drugs
|September 24, 2008
PubMed
Abstract

Insights

ASA404, a novel vascular disrupting agent (VDA), shows promise in treating non-small cell lung cancer (NSCLC). This VDA is well-tolerated and is currently in Phase III trials for NSCLC treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Tumor Biology

Background:

  • Antiangiogenic and vascular disrupting agents (VDAs) aim to inhibit tumor growth by disrupting blood flow and nutrient supply.
  • ASA404 represents a pioneering VDA, being the first to advance into Phase III clinical trials.

Purpose of the Study:

  • To review existing preclinical and clinical data for ASA404.
  • To evaluate the potential role of ASA404 within contemporary therapeutic strategies.

Main Methods:

  • A comprehensive literature search was conducted using the PubMed database.
  • Keywords included 'ASA404', 'AS1404', 'DMXAA', and related terms for clinical trials.

Main Results:

  • ASA404 is a tumor vascular disrupting agent.
  • The agent has demonstrated good tolerability in clinical studies.
  • Preliminary data suggest efficacy when combined with paclitaxel and carboplatin.

Conclusions:

  • ASA404 is a well-tolerated tumor VDA with demonstrated promise in non-small cell lung cancer (NSCLC) treatment.
  • Combination therapy with paclitaxel and carboplatin shows potential for NSCLC.
  • A confirmatory Phase III trial is underway to validate these findings.

More Related Videos

Assay Development for High-Throughput Drug Screening Against Mycobacteria07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...